Herzog Fox & Neeman acted as company counsel for Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), an Israeli clinical-stage specialty pharmaceutical company, in a follow-on underwritten public offering yielding gross proceeds totalling USD 70 million. Merrill Lynch, Pierce, Fenner & Smith Incorporated, Cowen and Company, LLC, Barclays Capital Inc. acted as joint book-running managers for the offering, and Cantor Fitzgerald & Co. acted as lead manager.

In addition, Foamix granted the underwriters an option to purchase additional shares for an aggregate gross amount of up to USD 5.67 million. If exercised, the option will bring the total gross proceeds from the offering to USD 75.7 milllion. The offering is expected to close on September 18, 2018.